Abstract
Dyslipoproteinemia is common in lupus patients. In this study, we investigated the pattern of dyslipoproteinemia in the course of active systemic lupus erythematosus (SLE) in possible association with anti-double-stranded DNA (anti-dsDNA) antibodies. Forty-six lupus patients under 45 years old who fulfilled the American College of Rheumatology revised criteria for the classification of SLE were selected. The exclusion criteria were renal failure, nephrotic syndrome, thyroid or liver disease, diabetes mellitus, obesity, pregnancy and taking drugs that induce dyslipidemia. Disease activity was measured by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Comparison of the lipid profiles, between active and inactive groups determined high levels of serum TG and VLDL and low levels of serum HDL in active group in comparison with inactive group(P < 0.05). The results indicated that the levels of TG and VLDL were significantly elevated in the patients with positive anti-dsDNA (P < 0.05). Although, the mean of serum HDL levels was also lower in patients with positive anti-dsDNA, the difference was not significant. This pattern of dyslipoproteinemia in active SLE may be associated with the autoimmune mechanisms especially in relation to the presence of anti-dsDNA antibodies.
Similar content being viewed by others
References
Formiga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R (2001) Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 10:359–363
Ettinger WH, Goldberg AP, Appelbaum-Bowden D, Hazzard WR (1987) Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 83:503–508
Petri M (2000) Detection of coronary artery disease and role of traditional risk factors in the Hopkins lupus Cohort. Lupus 9(3):170–175
Leong KH, Koh ET, Feng PH, Boey ML (1994) Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 21:1264–1267
Lahita RG, Rivkin E, Cavanagh I, Romano P (1993) Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 36:1566–1574
Ilowite NT, Samuel P, Ginzler E, Jacobson MS (1988) Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 31:859–863
Borba EF, Bonfá E (1997) Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 6:533–539
Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M (2002) Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 46:2957–2963
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Committee on prognosis studies in SLE. Derivation of the SLEDAI a: disease activity index for lupus patients. Arthritis Rheum 35:630–640
Warnick GR, Benderson J, Albers JJ (1982) Dextran sulfate–Mg2 + precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem 28:1379–1388
Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin chem 18:499–502
Gharavi AV, Lockshin MD (1997) Antiphospholipid antibodies. In: Rose NR, Macario EC, Folds JD, et al (eds) manual of clinical laboratory, 5th edn, ASM press Immunology, Washington DC, pp 949–953
Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegard J (2003) Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/ tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 48:2533–2540
Ilowite NT, Copperman N, Leicht T, Kwong T, Jacobson MS (1995) Effects of dietary modification and fish oil supplementation on dyslipoproteinemia in pediatric systemic lupus erythematosus. J Rheumatol 22:1347–1351
Ginsberg HN (1990) Lipoprotein physiology and its relationship to atherogenesis. Endocrinol Metab Clin North Am 19:211–228
Borba EF, Bonfa E, Vinagre CG, Ramires JA, Maranhao RC. Chylomicron (2000) Metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 43:1033–1040
Beaumont JL, Berard M, Antonucci M, Delplanque B, Vranckx R (1997) Inhibition of lipoprotein lipase activity by a monoclonal immunoglobulin in autoimmune hyperlipidemia. Atherosclerosis 26:67–77
Alverson DC, Chase HP (1977) Systemic lupus erythematosus in childhood presenting as hyperlipoproteinemia. J Pediatr 91:72–75
Delgado Alves J, Ames PR, Donohue S, Stanyer L, Nourooz-Zadeh J, Ravirajan C, Isenberg DA (2002) Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 46:2686–2694
Abe H, Tsuboi N, Suzuki S, Sakuraba H, Takanashi H, Tahara K,Tonozuka N,Hayashi T, Umeda M (2001) Anti- apolipoprotein A-I autoantibody: characterization of monoclonal autoantibodies from patients with systemic lupus erythematosus. J Rheumatol 28:990–995
Dinu AR, Merrill JT, Shen C, Antonov IV, Myones BL, Lahita RG (1998) Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 7:355–360
Lazarevic MB, Vitic J, Myones BL, Mladenovic V, Nanusevic N, Skosey JL, Swedler WI (1993) Antilipoprotein antibodies in rheumatoid arthritis. Semin Arthritis Rheum 22:385–391
Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC (1999) Serum IL-6, TNFα, p55 srTNFα, p75 srTNFα, srIL-2α levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 18:17–22
Semb H, Peterson J, Tavernier J, Olivecrona T (1987) Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol chem 262:8390–8394
Beutler BA, Cerami A (1985) Recombinant interleukin-1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol 135:3969–3971
Ehnholm C, Aho K, Huttunen JK, Kostiainen E, Mattila K, Pakkarainen J, Cantell K (1982) Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases. Arteriosclerosis 2:68–73
Kwiterovich PO Jr (1998) The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 82:13Q–21Q
Third report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III): final report. Circulation 106:3143–3420
Acknowledgment
We thank Dr. Farrokh Habibzadeh (M.D.) for his critical review of the manuscript. This work was supported by grant No: 1603, awarded by Shiraz University of Medical Sciences.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kashef, S., Ghaedian, M.M., Rajaee, A. et al. Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies. Rheumatol Int 27, 235–241 (2007). https://doi.org/10.1007/s00296-006-0195-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-006-0195-3